Evidence map›Paper›PMID 41102430›Full record

ArticleJournal of applied genetics2025

Carfilzomib resistance in multiple myeloma: A comparative metabolomic analysis.

Krzysztof Żyłka, Magdalena Łuczak, Magdalena Kostrzewska-Poczekaj, Kinga Bednarek, Arnold Bolomsky, Tadeusz Kubicki, Małgorzata Jarmuż-Szymczak, Heinz Ludwig, Dominik Dytfeld

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of applied genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Krzysztof ŻyłkaDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Ul. Szamarzewskiego 84, 60-569, Poznan, Poland.
Magdalena ŁuczakDepartment of Biomedical Proteomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Ul. Z. Noskowskiego 12/14, 61-704, Poznan, Poland. magdalu@ibch.poznan.pl.
Magdalena Kostrzewska-PoczekajInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Kinga BednarekInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Arnold BolomskyWilhelminen Cancer Research Institute, Department of Medicine I, Klinik Ottakring, Vienna, Austria.
Tadeusz KubickiDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Ul. Szamarzewskiego 84, 60-569, Poznan, Poland.
Małgorzata Jarmuż-SzymczakDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Ul. Szamarzewskiego 84, 60-569, Poznan, Poland.
Heinz LudwigWilhelminen Cancer Research Institute, Department of Medicine I, Klinik Ottakring, Vienna, Austria.
Dominik DytfeldDepartment of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Ul. Szamarzewskiego 84, 60-569, Poznan, Poland. dytfeld@me.com.ORCID http://orcid.org/0000-0003-0855-6591

Funding

Narodowe Centrum Nauki 2017/25/B/NZ5/01827
6 · The paper itself

Abstract

Proteasome inhibitors are currently at the forefront of multiple myeloma (MM) treatment. Drug resistance in MM challenges treatment, causing relapses and making the disease incurable. Urgent strategies are needed to combat resistance and understand its mechanisms. Targeting the metabolism of MM is a promising approach, as metabolic changes are associated with the disease and its adaptation to therapy. Metabolomics, the study of small molecule metabolites, is a powerful tool for identifying and analyzing a cell's metabolic phenotype. In this study, we aimed to investigate alterations in the metabolome of carfilzomib-resistant MM cells. We conducted global metabolomic comparative analyses of two carfilzomib-sensitive MM lines with their carfilzomib-resistant progenies. Additionally, we performed bioinformatic analysis to determine the top canonical pathways, biological functions, and upstream regulators linked to the differences in metabolomic profiles. Differential metabolite analysis showed increased amino acid and decreased fatty acid concentrations in carfilzomib-resistant cells. Functional analysis revealed increased glucose-6-phosphate oxidation and inhibited lipid accumulation in resistant lines. The bioinformatic analysis predicted PML, ARNT D-glucose, and UPC1 as upstream regulators of observed changes in carfilzomib-resistant cells. This study presents one of the first metabolomic profiles of two carfilzomib-resistant MM lines and the metabolome changes that may contribute to carfilzomib resistance.

Indexed as

CarfilzomibMetabolic adaptationMetabolomicsMultiple myelomaProteasome inhibitorsResistance

Identifiers

PMID41102430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.